AUG 7, 2026 · JOURNAL ARTICLE
Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead
Journal of Computational Biophysics and Chemistry
This is early-stage drug discovery work using computational and in vitro methods to identify a lead compound; it lacks any in vivo efficacy data, clinical outcomes, or human studies needed to support therapeutic claims.
Reported
Binding free energy (ΔG)-63.21 kcal/mol
IC50 (VEGFR-2 inhibition)0.086 ± 0.002 μM